OTCMKTS:BIXT Bioxytran (BIXT) Stock Price, News & Analysis → They say it’s ‘unstoppable’ – How I made 43,509% (From Investing Daily) (Ad) Free BIXT Stock Alerts $0.12 -0.02 (-14.29%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.11▼$0.1450-Day Range$0.10▼$0.1552-Week Range$0.07▼$0.54Volume88,741 shsAverage Volume175,213 shsMarket Capitalization$20.88 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get Bioxytran alerts: Email Address Ad Investing DailyThey say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.Click here now for the full story. About Bioxytran Stock (OTCMKTS:BIXT)Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.Read More BIXT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BIXT Stock News HeadlinesMarch 20, 2024 | msn.comBIXT: Carbohydrate Drug Design in the Fight Against VirusesMarch 6, 2024 | globenewswire.comBioxytran Announces Preprint of Shingles Case Study Showing Clearance Using a Topical Galectin-3 AntagonistApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.February 21, 2024 | finance.yahoo.comBioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19February 21, 2024 | globenewswire.comBioxytran's Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19October 24, 2023 | finance.yahoo.comBioxytran Gets Broad Patent Coverage on 60+ VirusesSeptember 14, 2023 | finance.yahoo.comBioxytran Announces Broad Spectrum Antiviral Activity Highlighted in ProLectin-MSeptember 6, 2023 | benzinga.comBioxytran Received IND Application by the FDA for Clinical Trials with ProLectin-M to Treat COVID-19 patientsApril 27, 2024 | Investing Daily (Ad)They say it’s ‘unstoppable’ – How I made 43,509% Not long ago I joined Phil Ash for a private one-on-one interview. And during our time together I pulled the covers of my investing system that’s delivered 779 winners and 43,509% total profits since November of 2015… Without a single loss.August 25, 2023 | msn.comFDA grants clearance to Bioxytran’s IND for Covid-19 trial initiationAugust 24, 2023 | finance.yahoo.comBioxytran Announces FDA Clearance of its IND Application for ProLectin-M in Clinical TrialsAugust 8, 2023 | finance.yahoo.comBioxytran Initiates a Registrational Trial of Oral ProLectin-M for Mild to Moderate COVID-19 PatientsJuly 31, 2023 | finance.yahoo.comBioxytran Names Leslie Ajayi as Interim CMO and Head of the Medical Advisory BoardJune 27, 2023 | it.tmcnet.comBioxytran Peer-Reviewed Journal in "Vaccines" Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 27, 2023 | finance.yahoo.comBioxytran Peer-Reviewed Journal in “Vaccines” Contains Mechanism Capable of Targeting Future COVID-19 MutationsJune 12, 2023 | msn.comBioxytran expands institutional investor base with $0.5M equity investmentJune 12, 2023 | finance.yahoo.comBioxytran Expands Institutional Investor Base with an additional $500,000 Equity InvestmentApril 19, 2023 | finance.yahoo.comBioxytran Tests Acellular Oxygen Carrier BXT-25 in Pre-Clinical TrialsMarch 29, 2023 | tmcnet.comBioxytran Announces Positive Phase 2 Trial Results were Featured in "Vaccines" a Peer-Reviewed JournalMarch 29, 2023 | finance.yahoo.comBioxytran Announces Positive Phase 2 Trial Results were Featured in “Vaccines” a Peer-Reviewed JournalMarch 6, 2023 | finance.yahoo.comBioxytran, Inc. (BIXT) Stock Historical Prices & Data - Yahoo FinanceFebruary 28, 2023 | finance.yahoo.comProLectin-M Demonstrates Significant Activity Against Influenza and Respiratory Syncytial VirusFebruary 22, 2023 | finance.yahoo.comNature Reviews Drug Discovery Article Offers Independent Support for ProLectin-I in Fibrosis and ProLectin-M as an Antiviral DrugFebruary 14, 2023 | finance.yahoo.comBioxytran to Appear on ClearThink IR’s Virtual Live EventFebruary 8, 2023 | proactiveinvestors.comBioxytran drug candidates ProLectin-M and ProLectin-I progressing as COVID-19 treatmentsFebruary 6, 2023 | finance.yahoo.comBioxytran Receives Approval to Initiate Trials with ProLectin-IDecember 28, 2022 | marketwatch.comBioxytran Shares Rise 20% on Trial Results for Covid-19 DrugSee More Headlines Receive BIXT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioxytran and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today4/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:BIXT CUSIPN/A CIK1445815 Webwww.bioxytraninc.com Phone(617) 454-1199FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,280,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-2,861.84% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / Book-12.00Miscellaneous Outstanding Shares173,980,000Free Float52,195,000Market Cap$20.88 million OptionableNot Optionable Beta-0.83 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. David Platt Ph.D. (Age 71)Chairman, CEO & President Comp: $420kMr. Michael Sheikh B.S. (Age 54)Chief Communication Officer Comp: $280kKey CompetitorsLipocineNASDAQ:LPCNAmarillo BiosciencesOTCMKTS:AMAREyenoviaNASDAQ:EYENDURECTNASDAQ:DRRXIterum TherapeuticsNASDAQ:ITRMView All Competitors BIXT Stock Analysis - Frequently Asked Questions How have BIXT shares performed in 2024? Bioxytran's stock was trading at $0.15 at the beginning of the year. Since then, BIXT shares have decreased by 20.0% and is now trading at $0.12. View the best growth stocks for 2024 here. Are investors shorting Bioxytran? Bioxytran saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 7,900 shares, a decline of 86.0% from the March 31st total of 56,600 shares. Based on an average daily volume of 468,400 shares, the short-interest ratio is presently 0.0 days. View Bioxytran's Short Interest. How were Bioxytran's earnings last quarter? Bioxytran, Inc. (OTCMKTS:BIXT) announced its quarterly earnings data on Friday, March, 22nd. The company reported ($0.01) EPS for the quarter. What other stocks do shareholders of Bioxytran own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bioxytran investors own include Achillion Pharmaceuticals (ACHN), ACADIA Pharmaceuticals (ACAD), Arbutus Biopharma (ABUS), Abacus Property Group (ABP), Advanced BioMedical Technologies (ABMT), Abiomed (ABMD), ARCA biopharma (ABIO), Abeona Therapeutics (ABEO) and Abcam (ABCZY). How do I buy shares of Bioxytran? Shares of BIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BIXT) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThey say it’s ‘unstoppable’ – How I made 43,509% Investing DailyThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioxytran, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
